Prof. Dehua Li | Peri-implantitis | Best Researcher Award

Posted on 28/12/202428/12/2024 by Pencis

Prof. Dehua Li | Peri-implantitis | Best Researcher Award

Air Force Medical University | China

Author Profile

🌟Biography of Dehua, Li 🦷🧬

Dr. Dehua Li is a researcher at the State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Air Force Medical University, Xi’an, China. His work bridges cutting-edge nanotechnology with transformative solutions in biomedicine, particularly for dental health applications.

🔬 Research Focus

Development and application of nanotechnology in biomedical fields
Innovative strategies for biofilm decontamination and peri-implantitis management in dental implantology
Design of pH-responsive drug delivery systems for precision medicine
Interdisciplinary approaches to integrating nanomaterial technologies into clinical solutions

💡 Key Contributions

Designed D-arginine-loaded pH-responsive mesoporous silica nanoparticles (Dar@MSN-COS) to target biofilms on dental implants effectively.
Spearheaded in vitro and in vivo studies demonstrating the biocompatibility and therapeutic potential of Dar@MSN-COS in treating peri-implantitis.
Advanced research into the synergistic effects of nanotechnology and mechanical decontamination techniques, such as water jet therapy, for improving implant reosseointegration.

🔧 Core Skills

Nanoparticle synthesis and functionalization
Advanced microscopy techniques, including SEM and CLSM
Expertise in drug release profiling, cytotoxicity assays, and biofilm characterization
Proficiency in analytical tools like FTIR, DLS, and statistical software (SPSS, GraphPad Prism)

🏆 Awards and Grants

Recipient of the Foundation of National Clinical Research Center for Oral Diseases (Grant NO: LCC202202)

With his innovative approaches and multidisciplinary expertise, Dr. Dehua Li is contributing to the advancement of precision medicine and oral health, fostering solutions that promise better outcomes in implantology and beyond.

🌏 CONCLUSION

In conclusion, Dr. Dehua Li is at the forefront of advancing dental health and precision medicine through his expertise in nanotechnology and biomaterials science. His innovative work in developing pH-responsive drug delivery systems and synergistic decontamination methods addresses critical challenges in peri-implantitis management and dental implantology.

📊🔬NOTABLE PUBLICATION:

Additive Manufacturing Technologies in the Oral Implant Clinic: A Review of Current Applications and Progress
- Authors: Huang, S., Wei, H., Li, D.
- Journal: Frontiers in Bioengineering and Biotechnology
- Year: 2023

Asperuloside Prevents Peri-Implantitis via Suppression of NF-κB and ERK1/2 on Rats
- Authors: Wang, X., Chen, X., Zhang, Z., Wei, H., Li, D.
- Journal: Pharmaceuticals
- Year: 2022

A Novel Technique for Implant-Supported Fixed Complete Rehabilitation Based on a Dynamic Virtual Patient
- Authors: Wang, J., Wu, Y.-L., Ma, J., Wu, F., Li, D.-H.
- Journal: Journal of Dentistry
- Year: 2023

Surgical Principles and the Decision-Making for Peri-Implant Keratinized Mucosa Augmentation
- Authors: Li, D.
- Journal: Chinese Journal of Stomatology
- Year: 2023

Influences of Standardized Clinical Probing on Peri-Implant Soft Tissue Seal in a Situation of Peri-Implant Mucositis: A Histomorphometric Study in Dogs
- Authors: Cai, R., Liu, Y., Wang, X., Lei, J., Li, D.
- Journal: Journal of Periodontology
- Year: 2024

Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Posted on 23/12/202423/12/2024 by Pencis

Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Sun Yat-sen University | China

AUTHOR PROFILE

Scopus

ORCID ID

🧑‍🔬 DR. SHI-LIANG HUANG

Associate Professor in Medicinal Chemistry
Sun Yat-sen University, People’s Republic of China

🎯 OBJECTIVE

Dedicated Associate Professor specializing in Medicinal Chemistry, with a passion for driving innovation in drug discovery and development, focusing on the tumor microenvironment and the heat shock response.

📘 EARLY ACADEMIC PURSUITS

Dr. Huang’s academic journey began with a solid foundation in Chemistry and Biochemistry, laying the groundwork for a distinguished career. After excelling in undergraduate studies, Dr. Huang pursued advanced degrees in Medicinal Chemistry, demonstrating exceptional aptitude for research and innovation.

Key achievements during this phase include:

Master’s Thesis: Groundbreaking work on natural product derivatives for therapeutic applications.
Doctoral Research: Advanced studies on the mechanisms of small molecules in altering biochemical pathways.

🏢 PROFESSIONAL ENDEAVORS

As an Associate Professor at Sun Yat-sen University, Dr. Huang has significantly contributed to the university’s reputation as a leading institution in medicinal research. His professional journey is marked by:

Leading Interdisciplinary Teams: Collaborating with experts in oncology, biochemistry, and computational modeling.
Research Innovation: Pioneering techniques in synthesizing inhibitors targeting heat shock proteins (HSPs) and heat shock factor 1 (HSF1).
Teaching Excellence: Mentoring students in natural medicinal chemistry and drug design methodologies.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Huang’s work revolves around integrating bioorganic chemistry with tumor microenvironment studies to innovate cancer therapies. Key contributions include:

Medicinal Chemistry: Developing novel molecules with high specificity for cancer-related targets.
Natural Product Exploration: Isolating and modifying natural compounds to enhance their therapeutic potential.
Heat Shock Response Modulation: Designing inhibitors to disrupt HSF1 and HSP pathways, which are critical in cancer cell survival under stress.
Tumor Microenvironment Studies: Investigating how microenvironmental factors influence drug efficacy.

🌟 IMPACT AND INFLUENCE

Dr. Huang’s research has had a profound impact on the scientific community and beyond:

Published Works: Author of numerous peer-reviewed articles in high-impact journals.
Citations and Recognition: Garnered widespread academic citations, reflecting the influence and applicability of his research.
Collaboration and Leadership: Actively involved in global collaborations, enhancing the translational impact of his findings.

📊 ACADEMIC CITATIONS AND METRICS

Dr. Huang’s academic metrics underscore his scholarly contributions:

H-Index: Demonstrates significant citation impact in medicinal chemistry and oncology.
Published Articles: Over 50 research papers, including breakthroughs in bioorganic and natural medicinal chemistry.
Research Grants: Secured funding for multiple national and international projects.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

As a visionary in drug discovery, Dr. Huang aspires to expand his research impact by:

Advancing precision medicine approaches tailored to the tumor microenvironment.
Developing next-generation inhibitors targeting stress-response proteins in cancer therapy.
Mentoring the next wave of researchers in innovative medicinal chemistry.

🌏 CONCLUSION

Dr. Shi-liang Huang embodies a blend of academic rigor, research innovation, and educational leadership. His contributions continue to shape the future of medicinal chemistry, with a legacy that inspires collaboration, discovery, and impactful solutions in cancer therapy.

📊🔬NOTABLE PUBLICATION:

A Novel HSF1 Activator Ameliorates Non-Alcoholic Steatohepatitis by Stimulating Mitochondrial Adaptive Oxidation
- Authors: Rao, Y.; Li, C.; Hu, Y.-T.; Ye, J.-M.; Huang, Z.-S.
- Journal: British Journal of Pharmacology
- Year: 2022

Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective c-MYC Transcription Repressors Targeting the Promoter G-Quadruplex
- Authors: Li, M.-L.; Yuan, J.-M.; Yuan, H.; Chen, S.-B.; Huang, Z.-S.
- Journal: Journal of Medicinal Chemistry
- Year: 2022

Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy
- Authors: Pan, X.; Mao, T.-Y.; Mai, Y.-W.; Huang, Z.-S.; Huang, S.-L.
- Journal: Molecules
- Year: 2022

Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer
- Authors: Jiang, X.-C.; Tu, F.-H.; Wei, L.-Y.; Chen, S.-B.; Huang, Z.-S.
- Journal: Journal of Medicinal Chemistry
- Year: 2022

Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer
- Authors: Xu, Y.-H.; Hu, Y.-T.; Xu, S.-M.; Chen, S.-B.; Huang, Z.-S.
- Journal: Journal of Medicinal Chemistry
- Year: 2023

Prof. Linghua Li | Cancer Science | Best Researcher Award

Posted on 16/12/202416/12/2024 by Pencis

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

B.S., Clinical Medicine, Medical School of Peking University (1997)
M.S., Internal Medicine, Sun Yat-sen University (2008)
Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
Visiting Scholar, UNC-Chapel Hill (2012)
Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Posted on 12/12/202412/12/2024 by Pencis

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Pfizer Japan Inc | Japan

AUTHOR PROFILE

ORCID ID

🏫 EARLY ACADEMIC PURSUITS

Mr. Toshitaka Hirano pursued his education in Japan, specializing in fields related to oncology and pharmaceutical sciences. His early academic years were marked by a strong commitment to understanding the mechanisms of malignancy and its risk factors, laying the foundation for his influential career.

💼 PROFESSIONAL ENDEAVORS

Currently associated with Pfizer, Mr. Hirano has established himself as a leading expert in the risk factor analysis of malignancy. His role includes conducting advanced research, collaborating with global teams, and integrating pharmaceutical innovation with clinical practice.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Hirano’s research is focused on identifying malignancy risk factors, particularly in patients with chronic conditions like rheumatoid arthritis. His studies examine the interplay between biological, environmental, and genetic factors contributing to cancer development. He has significantly advanced understanding in areas such as:

Immunogenicity risk associated with biologics
Cardiovascular events in rheumatic disease patients
Safety and effectiveness of novel therapies like tofacitinib

🌏 IMPACT AND INFLUENCE

Mr. Hirano’s work has had a profound impact on both clinical and research landscapes:

Policy and Practice: His findings inform public health guidelines and pharmaceutical strategies.
Patient Outcomes: Through his research, he has contributed to safer and more effective treatments for vulnerable populations.
International Collaboration: His global outreach ensures the dissemination of knowledge and best practices.

📚 ACADEMIC CITES

Mr. Hirano’s scholarly work is widely cited in high-impact journals, demonstrating its relevance and importance. Key publications include articles in International Journal of Rheumatic Diseases, Frontiers in Immunology, and Modern Rheumatology, highlighting his expertise in malignancy risk within rheumatic populations.

🏆 LEGACY AND FUTURE CONTRIBUTIONS ON MALIGNANCY

As a trailblazer in the field, Mr. Hirano is building a legacy of innovation and dedication to improving cancer outcomes. His future efforts aim to:

Develop predictive models for malignancy risks.
Enhance personalized medicine approaches.
Mentor the next generation of researchers in oncology and pharmaceutical sciences.

📌 OTHER IMPORTANT TOPICS

🔍 INTERDISCIPLINARY INTEGRATION

Mr. Hirano’s work bridges multiple fields, including oncology, immunology, and rheumatology, showcasing the value of a holistic research approach.

🌟 MENTORSHIP AND TEAM LEADERSHIP

He plays an active role in guiding young researchers and fostering collaborative environments that drive innovation.

🔔 PATIENT-CENTERED FOCUS

By emphasizing real-world data and patient-centered outcomes, Mr. Hirano ensures his work directly benefits those in need.

✨ CONCLUSION

Mr. Toshitaka Hirano’s dedication to malignancy risk analysis exemplifies the power of focused research to drive meaningful change. His work at Pfizer and beyond demonstrates a commitment to innovation, collaboration, and improving global health. With a legacy rooted in impactful research and a vision for a healthier future, Mr. Hirano continues to inspire and lead in the fight against cancer.

📊🔬NOTABLE PUBLICATION:

1️⃣ Risk Factors Associated With Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis in a Real-World Setting in Japan
- Authors: Kunihiro Yamaoka, Sugiyama N, Hoshi M, Jo JY, Kichul Shin, Hirano T
- Journal: International Journal of Rheumatic Diseases
- Year: 2024
2️⃣ Individual and Population-Level Variability in HLA-DR Associated Immunogenicity Risk of Biologics Used for the Treatment of Rheumatoid Arthritis
- Authors: Sugiyama N, Terry FE, Gutierrez AH, Hirano T, Hoshi M, Mizuno Y, Martin W, Yasunaga S, Niiro H, Fujio K, et al.
- Journal: Frontiers in Immunology
- Year: 2024
3️⃣ Six-Month Safety and Effectiveness of Tofacitinib in Patients With Rheumatoid Arthritis in Japan: Interim Analysis of Post-Marketing Surveillance
- Authors: Masataka Kuwana, Sugiyama N, Momohara S, Atsumi T, Takei S, Naoto Tamura, Masayoshi Harigai, Fujii T, Matsuno H, Takeuchi T, et al.
- Journal: Modern Rheumatology
- Year: 2024

Prof. Long Yang | Immunology | Best Researcher Award

Posted on 11/12/202411/12/2024 by Pencis

Prof. Long Yang | Immunology | Best Researcher Award

Tianjin University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

ORCID ID

LONG YANG, MD & PhD

🎓 EDUCATION

Doctor of Philosophy (PhD), Division of Experimental Medicine, Faculty of Medicine, McGill University, Canada (2005–2009)
Master of Medicine, Division of Pathology and Pathophysiology, Dalian Medical University, China (2000–2003)
Bachelor of Medicine (MD), Division of Clinical Medicine, Dalian Medical University, China (1989–1994)

🏢 EARLY ACADEMIC PURSUITS

Long Yang embarked on a robust academic journey with a foundational education in clinical medicine, followed by a specialization in pathology and pathophysiology. His PhD from McGill University further honed his expertise in experimental medicine, marking the start of an illustrious research career.

💼 PROFESSIONAL ENDEAVORS

Professor (2021–Present)
Institute of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, China.
Focused on advancing integrative medicine through innovative research and teaching.
Research Associate (2018–2020)
Lady Davis Institute, Jewish General Hospital, McGill University, Canada.
Contributed to cutting-edge research in cellular and molecular medicine.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Yang’s research interests lie at the intersection of integrative medicine and experimental cellular mechanisms. He has contributed significantly to understanding infectious diseases and cellular pathophysiology. His work bridges traditional Chinese medicine and contemporary medical research, fostering novel therapeutic strategies.

🌟 IMPACT AND INFLUENCE

Dr. Yang’s tenure in academia and research institutions has been marked by:

Publication of numerous peer-reviewed articles in high-impact journals.
Development of interdisciplinary approaches combining traditional medicine and modern science.
Recognition as a thought leader in cellular and infection microbiology.

📚 ACADEMIC CITATIONS

His research has earned widespread recognition, with citations underscoring the global relevance of his contributions to experimental medicine and integrative healthcare solutions.

🔗 PROFESSIONAL SERVICE

Associate Editor, Frontiers in Cellular and Infection Microbiology.
Played a pivotal role in curating impactful content, ensuring scientific rigor, and promoting advancements in the field.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Long Yang’s work continues to shape the integration of traditional and modern medical paradigms. His dedication to mentoring emerging scholars and contributing to healthcare innovations ensures a lasting legacy in both academia and clinical applications.

🌟CONCLUSION 🌿

Dr. Long Yang’s distinguished career as a researcher, educator, and practitioner showcases his unwavering dedication to advancing medicine through innovation and collaboration. By integrating traditional Chinese medicine with modern scientific methodologies, he has made a profound impact on healthcare, bridging cultural and academic divides.

📊🔬NOTABLE PUBLICATION:

The Gamble Between Oncolytic Virus Therapy and IFN
- Authors: Li, Q., Tan, F., Wang, Y., Yang, L., Cen, S.
- Journal: Frontiers in Immunology
- Year: 2022

Repurposing of HIV/HCV Protease Inhibitors Against SARS-CoV-2 3CLpro
- Authors: Ma, L., Li, Q., Xie, Y., Yang, L., Cen, S.
- Journal: Antiviral Research
- Year: 2022

SERINC5 Restricts Influenza Virus Infectivity
- Authors: Zhao, F., Xu, F., Liu, X., Liang, C., Guo, F.
- Journal: PLoS Pathogens
- Year: 2022

COVID-19 Pandemic: A Multidisciplinary Perspective on the Pathogenesis of a Novel Coronavirus from Infection, Immunity and Pathological Responses
- Authors: Yi, J., Miao, J., Zuo, Q., Kong, X., Yang, L.
- Journal: Frontiers in Immunology
- Year: 2022

Interferon-Inducible SAMHD1 Restricts Viral Replication Through Downregulation of Lipid Synthesis
- Authors: An, N., Ge, Q., Shao, H., Yang, L., Cen, S.
- Journal: Frontiers in Immunology
- Year: 2022

Prof. Jian Zaiyou | Botanical Drug | Best Researcher Award

Posted on 10/12/202410/12/2024 by Pencis

Prof. Jian Zaiyou | Botanical Drug | Best Researcher Award

Henan Institute of Science and Technology | China

AUTHOR PROFILE

Scopus

🎓EARLY ACADEMIC PURSUITS 🌱

Born in January 1973 in Huai Bin County, Henan Province, China, you began your academic journey with a keen interest in traditional Chinese medicine. Your pursuit of excellence led you to Beijing University of Chinese Medicine, where you obtained your Ph.D. in 2010. This foundational education equipped you with deep knowledge and expertise in medicinal botany and Chinese medicine, shaping your future academic and professional endeavors.

🏫PROFESSIONAL ENDEAVORS 🌿

Currently, you serve as an Associate Professor at the Henan Institute of Science and Technology, where you teach key subjects such as Chinese Medicine Processing, Chinese Medicine, and Medicinal Botany. Your teaching is enriched by practical applications and extensive research experience, fostering a deeper understanding of traditional Chinese medicinal practices among students.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BOTANICAL DRUG📚

Your research centers on the cultivation of medicinal plants, quality evaluation of Chinese medicine, and related fields. You have successfully presided over two research projects funded by the Science and Technology Department of Henan Province, which have significantly advanced the regional understanding of medicinal botany. Additionally, your contributions include authoring influential books such as:

Chinese Authentic Medicine
Wolfberry Practical Production Technology
Botany

Your work has provided practical and theoretical frameworks for improving the cultivation and processing of medicinal plants.

📖IMPACT AND INFLUENCE 🌟

With over 20 published scientific papers and 2 invention patents, your scholarly impact extends beyond Henan Province, influencing Chinese medicine practices at both regional and national levels. Your patents demonstrate innovation in the field, highlighting your commitment to improving traditional medicine through modern techniques.

📈ACADEMIC CITES 📝

Your contributions to Chinese medicine and botany have garnered attention in academic circles, with your work frequently cited in journals focused on medicinal botany, traditional medicine quality evaluation, and innovative cultivation techniques. These citations underline the importance of your research in advancing the field.

🚀LEGACY AND FUTURE CONTRIBUTIONS🌍

Your legacy lies in bridging traditional Chinese medicine with modern scientific approaches. By educating future generations and enhancing the quality standards of Chinese medicine, you have created a sustainable foundation for innovation in this field. Future contributions could include exploring global collaborations to integrate traditional Chinese medicine into international therapeutic practices and advancing the commercialization of medicinal botany technologies.

📚HIGHLIGHT 🌟

Through your dedicated teaching, pioneering research, and impactful publications, you have established yourself as a leading figure in the realm of Chinese medicine and medicinal botany. Your work not only preserves the rich traditions of Chinese medicine but also propels it into the future, ensuring its relevance in modern science and healthcare.

🌟CONCLUSION 🌿

Your journey from Huai Bin County to becoming an esteemed Associate Professor and researcher exemplifies dedication to advancing traditional Chinese medicine and medicinal botany. Through impactful teaching, innovative research, and valuable publications, you have significantly contributed to the preservation and modernization of Chinese medicinal practices. Your work has laid a robust foundation for future advancements, ensuring that the rich heritage of Chinese medicine continues to thrive in an evolving global healthcare landscape. As you expand your contributions, your influence will undoubtedly inspire new generations of scholars and practitioners, fostering a lasting legacy in the field.

📊🔬NOTABLE PUBLICATION:

Photosynthetic and Chlorophyll Fluorescence Characteristics of Isodon rubescens (Hemsley) H. Hara
- Authors: Zaiyou, J.; Xiuren, Z.; Jing, T.
- Journal: Scientific Reports
- Year: 2020

Evaluate the Photosynthesis and Chlorophyll Fluorescence of Epimedium brevicornu Maxim
- Authors: Zaiyou, J.; Xiaomin, T.; Hongsheng, W.; Guifang, X.
- Journal: Scientific Reports
- Year: 2022

Study on the Cause of Peeling and Withering in Isodon rubescens Stems in Winter
- Authors: Zaiyou, J.; Xiaomin, T.; Lei, D.
- Journal: Journal of King Saud University – Science
- Year: 2022

Analysis on the Quality of Epimedii folium Originating from Cultivated Epimedium pubescens Maxim
- Authors: Zaiyou, J.; Guifang, X.; Jing, T.
- Journal: Bangladesh Journal of Botany
- Year: 2021

Photosynthesis Capacity and Chlorophyll Fluorescence Characteristics of the Isodon rubescens (Hemsley) H. Hara Stem
- Authors: Zaiyou, J.I.A.N.; Susu, J.I.A.N.; Xiaomin, T.A.N.G.; Genhai, H.U.
- Journal: Scientific Reports
- Year: 2024

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

Posted on 03/12/202403/12/2024 by Pencis

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

The Chinese University of Hong Kong | China

Author Profile

Scopus

Dr. Wenjin Wang 🌟🔬

Postdoctoral Researcher | Tumor Photodynamic Therapy Expert | Biomolecular Phase Separation Investigator

Research Interests

Tumor Photodynamic Therapy (PDT) 💡🎯
- Design and synthesis of novel photosensitizers for PDT.
- Development of tumor-targeted PDT using tumor-responsive AIE (Aggregation-Induced Emission) photosensitizers.
Regulation of Biomolecular Phase Separation 🧬⚛️
- Investigation into the phase separation behaviors of biomolecules like proteins and nucleic acids.
- Modulation of these processes with chemical molecules to enhance understanding of intracellular organization and function.

Professional Experience

Postdoctoral Researcher 🏢
The Chinese University of Hong Kong, Shenzhen (07/2022–Present)
- Research on bioapplications of AIE materials under Prof. Ben Zhong Tang.
Biochemical Engineer 🧪
Shenzhen BGI Research Institute (10/2017–09/2018)
- Designed and optimized unnatural nucleotides for sequencing applications.
Laboratory Assistant 🔬
Peking University Shenzhen Graduate School (11/2016–10/2017)
- Focused on unnatural amino acids and asymmetric carbene O-H bond insertion catalysis by myoglobin proteins.
Research Associate 💊
Tianjin Institute of Pharmaceutical Research (08/2014–11/2016)
- Developed new hypoglycemic drugs through innovative designs and research.

Education

Ph.D. in Chemical Biology 🧫
Sun Yat-Sen University (09/2018–06/2022)
- Thesis: Antitumor mechanisms of metal complexes and their regulation on biomolecular phase separation behavior.
M.S. in Pharmacy 💊
Tianjin Medical University (09/2012–06/2015)
- Research: Development of SGLT2 inhibitors and hypoglycemic activity evaluation.
B.S. in Pharmacy 🏥
Tianjin Medical University (09/2008–06/2012)

Grants and Funding 💰📚

National Natural Science Foundation of China
- Ruthenium Complexes and Lipid Phase Separation in Antitumor Research (2024–2026, RMB 300K, Principal Investigator).
China Postdoctoral Science Foundation
- GGT-Activated AIE Photosensitizers for Tumor Photodynamic Therapy (2022–2025, RMB 80K, Principal Investigator).
Shenzhen Medical Research Fund
- Manipulable Aggregation of AIE Photosensitizers for Enhanced Tumor PDT (2025–2027, RMB 800K, Principal Investigator).
National Natural Science Foundation of China
- Phase Separation Mechanism of Antitumor Phosphor Metal Complexes (2022–2025, RMB 630K, Major Participant).
Yunnan Province Science and Technology Plan
- Aggregate Induced Luminescence in Biomass Resources (2024–2026, RMB 2000K, Major Participant).

Awards and Honors 🏆✨

Excellent Postdoctoral Doctor (Shenzhen, 12/2023).
National Scholarship for Doctoral Students (12/2021).
“Fran” Excellent Thesis Scholarship (Second Class, Sun Yat-sen University, 11/2021).
Excellent Wall Poster Award (32nd Academic Annual Meeting, Chinese Chemical Society, 04/2021).

Key Contributions 📈

Dr. Wang’s groundbreaking research combines innovative photodynamic therapies and the manipulation of biomolecular phase separation, driving advancements in cancer treatment and molecular biology.

📊🔬NOTABLE PUBLICATION:

Title: Multi-Stimuli-Responsive and Cell Membrane Camouflaged Aggregation-Induced Emission Nanogels for Precise Chemo-photothermal Synergistic Therapy of Tumors
- Authors: Zhang, L.; Wang, Z.; Zhang, R.; … Zhao, Z.; Tang, B.Z.
- Journal: ACS Nano
- Year: 2023

Title: Multi-site isomerization of synergistically regulated stimuli-responsive AIE materials toward multi-level decryption
- Authors: Zhong, W.; Zhang, J.; Lin, Y.; … Cai, X.-M.; Tang, B.Z.
- Journal: Chemical Science
- Year: 2024

Title: Chromene-based BioAIEgens: ‘in-water’ synthesis, regiostructure-dependent fluorescence and ER-specific imaging
- Authors: Cai, X.-M.; Lin, Y.; Zhang, J.; … Zhao, Z.; Tang, B.Z.
- Journal: National Science Review
- Year: 2023

Title: Natural Acceptor of Coumarin-Isomerized Red-Emissive BioAIEgen for Monitoring Cu²⁺ Concentration in Live Cells via FLIM
- Authors: Cai, X.-M.; Li, S.; Wang, W.-J.; … Zhao, Z.; Tang, B.Z.
- Journal: Advanced Science
- Year: 2024

Title: Room Temperature Phosphorescent Nanofiber Membranes by Bio-Fermentation
- Authors: Nie, X.; Gong, J.; Ding, Z.; … Qiu, Z.; Tang, B.Z.
- Journal: Advanced Science
- Year: 2024

Mr. Wenhui Wang | Macrophage | Best Researcher Award

Posted on 29/11/202429/11/2024 by Pencis

Mr. Wenhui Wang | Macrophage | Best Researcher Award

The First Affiliated Hospital of Dalian Medical University | China

AUTHOR PROFILE

Scopus

📚EARLY ACADEMIC PURSUITS

Wenhui wang’s academic journey began with a strong foundation in medical imaging, completing a bachelor’s degree in medical imaging at shanxi medical university fenyang college in 2021. He then pursued a master’s in radiological imaging at shanxi medical university, graduating in july 2024. His dedication to advancing medical imaging continues with his current ph.d. Study in imaging medicine and nuclear medicine at dalian medical university, where he is engaged in cutting-edge research.

🧑‍🔬PROFESSIONAL ENDEAVORS

Wenhui wang has embarked on a promising research career in the field of medical imaging and radiological science, particularly focused on macrophage tracking, stem cell imaging, and the development of advanced imaging probes. He is a principal investigator for several significant research projects in shanxi, including the development of new contrast agents for dynamic studies and the study of molecular imaging in the diagnosis and assessment of osteogenic and chondrogenic tumors like osteosarcoma and chondrosarcoma.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON MACROPHAGE

His research interests span a range of innovative topics, including macrophage tracking imaging, stem cell repair of osseocartilaginous defects, and the application of imaging for the diagnosis of traumatic and tumorous lesions in bones and joints. He is particularly interested in understanding the role of nano-molecular probes and developing novel imaging agents to improve diagnosis and treatment predictions in oncology and infectious diseases.

IMPACT AND INFLUENCE 🌍

Wenhui wang’s research has the potential to significantly impact the fields of radiological imaging, medical diagnostics, and stem cell research. His work in the development of nano-probes for molecular imaging could lead to advancements in the early diagnosis of cancer and improve the understanding of tumor behavior. Additionally, his study of stem cell therapy and cartilage repair could open new avenues in regenerative medicine.

AWARDS AND HONORS 🏅

Wang has received several academic awards for his exceptional performance and contributions to the field, including the master’s national scholarship, multiple university-level prizes, and recognition in competitions like the zhongqing cup national college student mathematical modeling competition. These awards reflect his outstanding academic achievements and dedication to excellence.

ACADEMIC CITES AND RECOGNITION 📜

Wang’s research has garnered increasing attention in the field of medical imaging, particularly through his pioneering studies in the application of technologies in tumor diagnosis and stem cell repair. His work is expected to contribute to future clinical practices and influence future research directions in the medical imaging community.

LEGACY AND FUTURE CONTRIBUTIONS 🔮

Wenhui wang is set to leave a lasting legacy in the fields of radiological imaging and stem cell therapy. His innovative research on advanced imaging agents and stem cell interventions could not only improve the diagnosis and treatment of cancer and bone diseases but also pave the way for new clinical applications in regenerative medicine. His future work has the potential to transform the way we approach medical imaging and treatment predictions.

🔗 CONCLUSION

Wenhui Wang is an emerging talent in the fields of medical imaging and nuclear medicine, with a strong foundation in radiological imaging and a forward-thinking research agenda. His work, focusing on macrophage tracking, stem cell therapy, and the development of novel imaging probes, positions him at the forefront of medical imaging advancements. Through his groundbreaking research, he has already demonstrated significant contributions to the understanding and treatment of osteogenic and chondrogenic tumors, as well as the enhancement of cartilage repair techniques.

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Posted on 26/11/202426/11/2024 by Pencis

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Yueyang Central Hospital | China

AUTHOR PROFILE

ORCID ID

📚EARLY ACADEMIC PURSUITS

ZENG QINGJUN completed his Master’s degree at Xiangya Medical College, Central South University, in 2010. This prestigious institution provided a strong foundation in medical education, equipping him with the skills and knowledge necessary for his future in the field of gastrointestinal surgery. His academic training allowed him to develop expertise in complex surgical techniques, laying the groundwork for his career as a clinical specialist in surgery.

⚕️PROFESSIONAL ENDEAVORS

Since July 2010, ZENG QINGJUN has been working in the field of gastrointestinal surgery, focusing on laparoscopic techniques for treating gastric and colorectal cancers. As a chief physician, he plays a pivotal role in leading surgical teams, performing high-risk surgeries, and making critical decisions for patient care. His clinical expertise and skillful handling of over 200 laparoscopic gastric cancer surgeries and 400 laparoscopic colorectal cancer surgeries are testaments to his proficiency in minimally invasive surgical methods. His surgical outcomes have contributed significantly to improving the quality of life for cancer patients and are recognized within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON GASTROINTESTINAL TUMORS

Dr. ZENG has dedicated much of his professional life to the development and refinement of laparoscopic surgical techniques in the treatment of gastrointestinal cancers. His research is heavily focused on advancing minimally invasive surgery, particularly in the areas of gastric cancer and colorectal cancer. Through clinical trials and innovative methodologies, he has been involved in optimizing surgical procedures to ensure better postoperative recovery, reduced complications, and more efficient treatment pathways for cancer patients.

🌍IMPACT AND INFLUENCE

Dr. ZENG QINGJUN has made an immense impact on the practice of gastrointestinal surgery in China, particularly in the realm of laparoscopic surgery. His innovative approaches and commitment to cutting-edge techniques have influenced both local and national surgical practices. His contribution to gastric and colorectal cancer surgery has improved patient outcomes and has set new standards in the field. As a chief physician, he mentors younger surgeons and shares his expertise, ensuring the continued progress of surgical techniques.

📑ACADEMIC CITATIONS

While detailed citation metrics are not provided, Dr. ZENG’s extensive clinical experience and research endeavors have led to his recognition in academic circles. His focus on laparoscopic techniques and cancer surgery continues to influence current and future generations of surgeons and researchers in the field. His work, particularly in gastric and colorectal cancer, has made notable contributions to medical literature and has been referenced in various academic and clinical studies.

🌱LEGACY AND FUTURE CONTRIBUTIONS

Dr. ZENG QINGJUN’s career reflects a legacy of excellence in surgical practice and medical innovation. His pioneering work in laparoscopic surgery and cancer treatment has already set the stage for future breakthroughs in the field of gastrointestinal oncology. Looking forward, he is likely to contribute even more significantly to surgical research, possibly expanding his focus to robot-assisted surgeries, postoperative care advancements, and the integration of AI in surgical planning. His mentorship, both locally and nationally, will shape the future of surgical education and the next generation of gastrointestinal surgeons.

💼LEADERSHIP IN SURGICAL PRACTICE

Dr. ZENG continues to hold a significant leadership role in the surgical department at his medical institution. His capacity as chief physician enables him to make high-level decisions in clinical practice, direct surgical teams, and implement best practice guidelines. His strategic leadership in gastrointestinal surgery helps to establish protocols for laparoscopic surgeries, improving surgical outcomes, and pushing the boundaries of traditional approaches.

🔗 CONCLUSION

Dr. Zeng Qingjun is a distinguished gastrointestinal surgeon whose work has significantly advanced the field of laparoscopic surgery for gastric and colorectal cancers. With over a decade of experience and hundreds of successful surgeries, his contributions have set new standards in minimally invasive surgical techniques, improving patient outcomes and recovery times. Through his leadership as chief physician, he has not only influenced clinical practices but has also become a mentor to aspiring surgeons, ensuring the continuity of high-quality surgical education.

📊🔬NOTABLE PUBLICATION:

1. Title: Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway
Authors: Qingjun Zeng, Sanjun Zhang, Linfang He, Qingyan Fu, Li Liao, Linjie Chen, Xiang Ding
Journal: Cancer Biotherapy and Radiopharmaceuticals
Year: 2023

2. Title: Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells
Authors: Xiang Ding, Qingyan Fu, Weixing Chen, Linjie Chen, Qingjun Zeng, Sanjun Zhang, Linfang He
Journal: Cell Biology International
Year: 2022

Prof. Ming-Yow Hung | Cardio-Oncology | Best Researcher Award

Posted on 26/11/202426/11/2024 by Pencis

Prof. Ming-Yow Hung | Cardio-Oncology | Best Researcher Award

Taipei Medical University | Taiwan

Author Profile

Scopus

ORCID ID

Biography: Prof. Ming-Yow Hung, MD, PhD 🌟💖🩺

Name: Prof. Ming-Yow Hung
Citizenship: Taiwanese

🎓 Education:

Medical Degree: School of Medicine, College of Medicine, Chang Gung University (1989–1995).
PhD: Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine (2007–2017).

🎖 Military Service:

Lieutenant General Physician, Navy, Taiwan, Republic of China (1996–1998).

💼 Professional Roles:

Attending Cardiologist: Division of Cardiology, Shuang Ho Hospital, Taipei Medical University (2008–present).
Professor of Medicine: Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University (since 2022).

🏅 Board Certifications:

Internal Medicine (2001).
Adult Cardiology (2004).

🔬 Research Interests:

Interventional Cardiology
Echocardiography
Basic Cardiovascular Science

📜 Editorial Contributions:

Editorial Board Member:
- Enliven: Clinical Cardiology and Research (2015–present).
- Journal of Epidemiological Research (2015–present).
- SM Vascular Medicine (2015–present).
Guest Editor:
- Journal of Interventional Cardiology (2019–2020).
- Oxidative Medicine and Cellular Longevity (2023).
- Frontiers in Cardiovascular Medicine (2023).
- Life (2023).

🎯 Research Projects:

Investigating macrophage polarization in coronary artery spasm using CRISPR core facilities (2020–2021).
Mechanisms of Garcinol as α-7nAChRs Inhibitor in cardiac damage (2021–2022).
LPCAT4/GDE7 axis as therapeutic targets in coronary artery spasm (2022–2023).
SCAP/SREBPs signaling in lipoprotein(a)-induced macrophage polarization (2023–2026).

🌟 Professional Affiliations:

Fellow, American Heart Association (2013–present).
Fellow, American College of Cardiology (2014–present).
Member of multiple Taiwanese and international cardiology societies.

🏆 Honors and Awards:

Clinical Medicine Research Award, Taipei Medical University (2014, 2015).
Recognition for outstanding contributions to cardiovascular research and patient care.

Prof. Hung is renowned for his dedication to advancing cardiovascular science, particularly in coronary artery spasm and interventional cardiology. 🌍❤️

🔗 CONCLUSION

Prof. Ming-Yow Hung is a distinguished cardiologist and academic leader, whose expertise in interventional cardiology, echocardiography, and cardiovascular science has earned him national and international recognition. As a Full Professor at Taipei Medical University and a Fellow of esteemed cardiology organizations, he has made significant contributions to both clinical practice and research.

📊🔬NOTABLE PUBLICATION:

Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory α 7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm
- Authors: Lin, Y.-K.; Yeh, C.-T.; Kuo, K.-T.; Hu, P.; Hung, M.-Y.
- Journal: Oxidative Medicine and Cellular Longevity
- Year: 2022

The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review
- Authors: Karimabad, M.N.; Kounis, N.G.; Hassanshahi, G.; Hung, M.-Y.; Nadimi, A.E.
- Journal: Vaccines
- Year: 2021

The Effect of Long COVID-19 Infection and Vaccination on Male Fertility: A Narrative Review
- Authors: Pourmasumi, S.; Nazari, A.; Ahmadi, Z.; Altay, S.; Kounis, N.G.
- Journal: Vaccines
- Year: 2022

“When,” “Where,” and “How” of SARS-CoV-2 Infection Affects the Human Cardiovascular System: A Narrative Review
- Authors: Kounis, N.G.; Gogos, C.; de Gregorio, C.; Velissaris, D.; Koniar, I.
- Journal: Balkan Medical Journal
- Year: 2024

Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review
- Authors: Hung, M.-J.; Yeh, C.-T.; Kounis, N.G.; Hu, P.; Hung, M.-Y.
- Journal: International Journal of Molecular Sciences
- Year: 2023